2025 Weight Loss Drug Study: What Research Shows

With dozens of weight loss medications now available or in late-stage development, clinicians and patients face an increasingly complex landscape of choices. A landmark 2025 systematic review and network meta-analysis published in The BMJ offers the most comprehensive evidence summary to date — analyzing 262 randomized controlled trials, nearly 100,000 participants, and 19 different drugs to help inform those decisions. Here is what the research found, and why it matters for anyone navigating obesity treatment today.

What This Study Found

The study — authored by Nong K, Shi Q, Xie X, and colleagues and published in The BMJ in 2026 (PMID: 42419792) — used frequentist random effects models and Bayesian dose-response models to compare the benefits and harms of obesity drugs against lifestyle modification alone over approximately one year of treatment.

Weight loss outcomes varied substantially across agents. Compared with lifestyle modification alone, researchers found the following mean reductions in body weight at one year (with moderate to high certainty evidence):

• Tirzepatide: –14.9% (95% CI: –16.0% to –13.9%)
• Cagrilintide-semaglutide (CagriSema): –14.8% (95% CI: –16.9% to –12.7%)
• Oral semaglutide: –10.9% (95% CI: –12.7% to –9.1%)
• Orforglipron: –9.9% (95% CI: –12.4% to –7.5%)
• Subcutaneous semaglutide: –9.8% (95% CI: –10.6% to –9.1%)
• Phentermine-topiramate: –8.1% (95% CI: –9.7% to –6.5%)

Emerging agents — including ecnoglutide, mazdutide, and retatrutide — showed estimated reductions of 13.1% to 14.6%, though the certainty of evidence for these drugs was rated very low to low, meaning findings should be interpreted cautiously.

The study also examined harms. Discontinuation due to adverse events was highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide, with risk ratios ranging from 1.9 to 4.2 compared with placebo or lifestyle modification. Gastrointestinal events were most frequently increased with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios 3.1 to 4.2). Fatigue risk was notably elevated with naltrexone-bupropion (risk ratio 8.9; an absolute increase of 331 additional cases per 1,000 people over one year), orforglipron, and CagriSema.

Body composition findings were notable. Tirzepatide produced the greatest reduction in fat mass (–25.7%), but also the greatest reduction in lean mass (–8.3%), raising questions about the long-term implications of lean mass loss alongside fat loss — a distinction researchers flagged as clinically relevant.

Cardiovascular and mortality outcomes showed meaningful signals only for certain agents. Subcutaneous semaglutide was the only drug associated with reduced all-cause mortality (risk ratio 0.81, 95% CI: 0.72 to 0.93) and reduced risk of myocardial infarction (risk ratio 0.72, 95% CI: 0.61 to 0.85), though the researchers noted these estimates were largely informed by cardiovascular outcome trials conducted in high-risk populations. Both subcutaneous semaglutide and tirzepatide were associated with reduced heart failure risk. No drug convincingly reduced kidney failure risk.

Quality of life improvements were limited. Across 43 trials involving 45,663 participants, no drug improved quality of life beyond the established minimally important difference of 10 points — all mean differences were below 5 points.

Clinical Significance

The breadth of this analysis — 262 trials, 99,791 participants, and 24 outcomes evaluated — gives it considerable weight in the clinical literature. The researchers' core finding is that larger weight reductions generally come with greater harms and higher rates of treatment discontinuation, a tradeoff that has direct implications for how clinicians and patients approach medication selection.

The study suggests that no single drug dominates across all outcomes. Tirzepatide and CagriSema may offer the greatest weight reduction, but they also carry meaningful adverse event profiles. Subcutaneous semaglutide, while producing somewhat less weight loss, appears to be the only agent with moderate-to-high certainty evidence supporting reductions in cardiovascular mortality and myocardial infarction risk — benefits that extend well beyond weight loss alone.

The lean mass findings deserve particular attention from clinicians. The researchers found that tirzepatide reduced lean mass by 8.3% alongside fat mass reduction — a consideration that may be especially relevant for older adults, individuals with sarcopenia risk, or those whose functional capacity could be impaired by skeletal muscle loss. This finding underscores the importance of evaluating body composition outcomes, not just total body weight, when assessing treatment success.

The quality-of-life data is also clinically sobering. Despite significant weight reductions, the study found that patients did not experience meaningful improvements in quality of life by standard measures. Researchers suggest this should factor into shared decision-making conversations, particularly when patients are weighing substantial medication costs, adherence burdens, and side effect profiles against expected outcomes.

Current Access and Compliance Context

The findings of this meta-analysis land at a moment when access to these medications remains highly variable. Injectable GLP-1 receptor agonists such as subcutaneous semaglutide and tirzepatide have faced persistent supply shortages in many markets, and insurance coverage remains inconsistent — leaving many patients unable to sustain treatment even when it is clinically indicated.

The emergence of oral formulations, such as oral semaglutide and the investigational oral agent orforglipron, may reduce some of the adherence and access barriers associated with injectable therapies. However, the study found that oral semaglutide carried a high rate of gastrointestinal adverse events and treatment discontinuation, suggesting that easier administration does not automatically translate to better tolerability or long-term compliance.

The researchers also noted that subgroup analyses across drug dosages and key patient characteristics — including age, sex, and baseline BMI — did not identify credible differences in relative treatment effects, with one exception: longer trial duration was associated with larger weight reductions for subcutaneous semaglutide. This finding suggests that sustained treatment may be necessary to capture the full benefit of certain agents, further highlighting the importance of access and adherence infrastructure.

What Patients Should Know

If you or someone you care for is considering medication for obesity or overweight, this research offers several important takeaways — though it is essential to discuss them with a qualified healthcare provider before making any treatment decisions.

More weight loss does not always mean better overall outcomes. The study suggests that the drugs producing the largest weight reductions also tend to carry the highest rates of side effects and treatment discontinuation. Understanding the full benefit-harm tradeoff is essential.

Cardiovascular risk profile matters. The mortality and heart attack risk reductions associated with subcutaneous semaglutide were largely seen in high-risk cardiovascular populations. Whether these benefits extend to lower-risk individuals is less certain based on current evidence.

Lean mass loss is a real consideration. Particularly with tirzepatide, the reduction in lean (muscle) mass alongside fat mass is a finding worth discussing with your provider — especially if physical strength, mobility, or metabolic health are priorities.

Quality of life improvements may be modest. Despite significant weight changes, the research found that patients did not consistently report meaningful improvements in quality of life measures, which is an important expectation to calibrate before starting treatment.

Long-term data is still emerging. Several of the newer agents reviewed in this study have limited long-term safety data, and the researchers rated certainty of evidence as very low to low for some emerging compounds. This does not mean they are unsafe, but it does mean the full picture is still developing.

Conclusion

This comprehensive network meta-analysis represents one of the most rigorous comparisons of obesity pharmacotherapy published to date, offering clinicians and patients a clearer — if still nuanced — picture of what these medications can and cannot do. The study reinforces that obesity treatment is not one-size-fits-all, and that decisions about medication should be made collaboratively, with full consideration of individual health goals, risk profiles, and values.

If you are interested in exploring evidence-based options for weight management under qualified medical supervision, the Peptide Association can help connect you with a knowledgeable provider. Visit peptideassociation.org/find-a-doctor to find a physician in your area who is trained in current obesity medicine and peptide therapeutics.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The information presented is based on a published peer-reviewed study and is provided to support informed conversations between patients and their healthcare providers. Always consult a licensed and qualified medical professional before starting, stopping, or changing any medication or treatment plan.

---

Citation (AMA format): Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026;e372161. doi:10.1136/bmj-2026-372161. PMID: 42419792.